ABSTRACT
Malignant diseases remain a leading cause of mortality and disability worldwide despite impressive advances in early diagnosis and treatment.
Immunotherapy is one of the many experimental treatments that have been proposed over four decades (1), melanoma and bladder tumors being among the first cancers targeted. Besides a steeply rising incidence [in 2000, roughly 60,000 new diagnosed melanomas and 16,000 deaths in Europe (2)], an important particularity of melanoma is its immunogenicity, early recognized and challenged with various clinical immunization protocols.
